Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other financing activities (2019 - 2024)

Historic Other financing activities for NovaBay Pharmaceuticals (NBY) over the last 5 years, with Q2 2024 value amounting to $96000.0.

  • NovaBay Pharmaceuticals' Other financing activities fell 6734.69% to $96000.0 in Q2 2024 from the same period last year, while for Mar 2025 it was $96000.0, marking a year-over-year decrease of 5200.0%. This contributed to the annual value of $115000.0 for FY2024, which is 3646.41% down from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported Other financing activities of $96000.0 as of Q2 2024, which was down 6734.69% from $19000.0 recorded in Q1 2024.
  • Over the past 5 years, NovaBay Pharmaceuticals' Other financing activities peaked at $294000.0 during Q2 2023, and registered a low of -$113000.0 during Q4 2023.